Research on the Use of Probiotics in the Prevention and Treatment of Inflammatory Bowel Disease
Application Research of Lactobacillus Reuteri in the Treatment of Inflammatory Bowel
Wecare Probiotics Co., Ltd.
50 participants
Jan 1, 2025
INTERVENTIONAL
Conditions
Summary
This project involves the use of oral Lactobacillus reuteri as an adjunct therapy for 8 weeks. Endoscopic observation of intestinal inflammation will be conducted at 1 month, 3 months, 6 months, and 12 months after the administration of the drug. Intestinal fluid will be collected endoscopically for 16S RNA analysis to assess changes in the gut microbiota. Inflammatory changes in the patients will be detected through peripheral blood tests, and fecal calprotectin levels will be measured to evaluate the progression of the disease.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
The experimental phase of the study lasts 8 weeks and each patient will be visited 4 times (January, March, June, and December).
The experimental phase of this study had last 8 weeks and each patient will make 4 visits (January, March, June, and December).
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06781827